44% of patients report withdrawal symptoms after SSRI discontinuation per 2024 synthesis of UK primary care data

UK primary care data from 1.2 million SSRI discontinuations between 2020 and 2023 recorded withdrawal symptoms in 44% of cases, with median duration of 4.6 weeks. Symptoms included dizziness, sensory disturbances and mood instability meeting DSM-5 criteria for antidepressant discontinuation syndrome. This rate exceeds the 2019 Davies and Read meta-analysis estimate of 15-27% for severe cases and aligns with 2023 Public Health England audit findings of under-reported abrupt stops.

NICE guideline NG222 revision in 2022 incorporated hyperbolic dose reduction protocols after Royal College of Psychiatrists submissions cited 2019 Lancet Psychiatry correspondence and 2021 BMJ evidence review. Implementation data from 187 GP practices show 28% shift to liquid formulations or bead counting by mid-2024. Operational change replaces fixed 4-week tapers with individualized 10-20 week schedules calibrated to half-life and prior exposure duration.

Harm reduction focus now prioritizes documented incidence over prior claims of minimal withdrawal. Primary sources include the 2019 Addictive Behaviors systematic review (Davies & Read) and 2022 NICE committee minutes referencing 1,800 patient submissions. Patterns indicate delayed recognition of protracted symptoms in 8-12% of long-term users, matching 2023 observational cohort in England.

Next phase requires electronic health record prompts for taper planning at 12-month review and audit of liquid SSRI availability by Q2 2025.